202 related articles for article (PubMed ID: 38815057)
1. New targets and mechanisms of action for lipid-lowering and anti-inflammatory therapies in atherosclerosis: where does the field stand?
Nicholls SJ; Nelson AJ
Expert Opin Ther Targets; 2024 May; 28(5):375-384. PubMed ID: 38815057
[TBL] [Abstract][Full Text] [Related]
2. Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis.
Bertrand MJ; Tardif JC
Expert Opin Emerg Drugs; 2017 Mar; 22(1):1-26. PubMed ID: 27927063
[TBL] [Abstract][Full Text] [Related]
3. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
4. Targeting the Cholesterol Paradigm in the Risk Reduction for Atherosclerotic Cardiovascular Disease: Does the Mechanism of Action of Pharmacotherapy Matter for Clinical Outcomes?
Zhou R; Stouffer GA; Smith SC
J Cardiovasc Pharmacol Ther; 2021 Nov; 26(6):533-549. PubMed ID: 34138676
[TBL] [Abstract][Full Text] [Related]
5. Lipid pharmacotherapy for treatment of atherosclerosis.
Nicholls SJ; Pisaniello AD; Kataoka Y; Puri R
Expert Opin Pharmacother; 2014 Jun; 15(8):1119-25. PubMed ID: 24702590
[TBL] [Abstract][Full Text] [Related]
6. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
Rosenblit PD
Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
[TBL] [Abstract][Full Text] [Related]
7. From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk.
Shapiro MD; Fazio S
Circ Res; 2016 Feb; 118(4):732-49. PubMed ID: 26892970
[TBL] [Abstract][Full Text] [Related]
8. Lipoprotein(a): cardiovascular risk and emerging therapies.
Fujino M; Nicholls SJ
Expert Rev Cardiovasc Ther; 2023 Apr; 21(4):259-268. PubMed ID: 37010028
[TBL] [Abstract][Full Text] [Related]
9. Novel emerging therapies in atherosclerosis targeting lipid metabolism.
Gupta M; Blumenthal C; Chatterjee S; Bandyopadhyay D; Jain V; Lavie CJ; Virani SS; Ray KK; Aronow WS; Ghosh RK
Expert Opin Investig Drugs; 2020 Jun; 29(6):611-622. PubMed ID: 32363959
[TBL] [Abstract][Full Text] [Related]
10. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
Tenenbaum A; Fisman EZ; Motro M; Adler Y
Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
[TBL] [Abstract][Full Text] [Related]
11. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.
Kones R
Vasc Health Risk Manag; 2013; 9():617-70. PubMed ID: 24174878
[TBL] [Abstract][Full Text] [Related]
12. An update on emerging drugs for the treatment of hypercholesterolemia.
Nelson AJ; Bubb K; Nicholls SJ
Expert Opin Emerg Drugs; 2021 Dec; 26(4):363-369. PubMed ID: 34842495
[TBL] [Abstract][Full Text] [Related]
13. Targeting triglycerides to lower residual cardiovascular risk.
Bubb KJ; Nelson AJ; Nicholls SJ
Expert Rev Cardiovasc Ther; 2022 Mar; 20(3):185-191. PubMed ID: 35323080
[TBL] [Abstract][Full Text] [Related]
14. Emerging drugs for hyperlipidemia.
Paras C; Hussain MM; Rosenson RS
Expert Opin Emerg Drugs; 2010 Sep; 15(3):433-51. PubMed ID: 20423271
[TBL] [Abstract][Full Text] [Related]
15. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
Evans M; Roberts A; Davies S; Rees A
Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
[TBL] [Abstract][Full Text] [Related]
16. Jeremiah Metzger Lecture: cholesterol, inflammation and atherosclerotic cardiovascular disease: is it all LDL?
Gotto AM
Trans Am Clin Climatol Assoc; 2011; 122():256-89. PubMed ID: 21686232
[TBL] [Abstract][Full Text] [Related]
17. Atherogenic Lipoproteins for the Statin Residual Cardiovascular Disease Risk.
Yanai H; Adachi H; Hakoshima M; Katsuyama H
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362288
[TBL] [Abstract][Full Text] [Related]
18. Lipid-Modifying Drugs: Pharmacology and Perspectives.
Xu RX; Wu YJ
Adv Exp Med Biol; 2020; 1177():133-148. PubMed ID: 32246446
[TBL] [Abstract][Full Text] [Related]
19. Emerging Cholesterol Modulators for Atherosclerotic Cardiovascular Disease.
Noh S; Mai K; Shaver M; Yong S; Mostaghimi M; Oh G; Radwan MM
Am J Med Sci; 2022 May; 363(5):373-387. PubMed ID: 35081404
[TBL] [Abstract][Full Text] [Related]
20. Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective.
Kones R
Drug Des Devel Ther; 2010 Dec; 4():383-413. PubMed ID: 21267417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
